Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tryptamine Therapeutics ( (AU:ENP) ) has issued an update.
Entropy Neurodynamics Limited has successfully completed the first patient dosing in its clinical trial for treating Binge Eating Disorder using TRP-8803, an IV-infused psilocin. This trial aims to provide controlled psychedelic experiences, which are crucial for the company’s strategy in delivering consistent psychedelic psychotherapy. The completion of this milestone, including DSMB safety clearance, sets the stage for further patient dosing and the potential for meaningful data that could support broader applications of TRP-8803 in treating eating disorders and other neuropsychiatric conditions.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing psychedelic-assisted therapies. The company collaborates with institutions like Swinburne University to conduct clinical trials, particularly targeting neuropsychiatric conditions such as Binge Eating Disorder.
Average Trading Volume: 2,473,976
Technical Sentiment Signal: Sell
Current Market Cap: A$54.72M
For an in-depth examination of ENP stock, go to TipRanks’ Overview page.